Expressing the sense of the House of Representatives that biotechnology firms meeting small business standards are critical to the United States, its people and its economy because they create new medicines, services, and jobs and meet unmet needs related to populations and patients with infectious and chronic diseases, including those of medically underserved populations.
Latest action · Mar 12, 2010 Referred to the House Committee on Energy and Commerce.
Progress
Where this resolution reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried. A simple resolution is the business of one chamber alone: it is not sent to the other chamber or to the President, and does not become law.
- IntroducedMar 12, 2010
- Agreed to in HouseNot reached
Summary
Recognizes: (1) that the public deserves the safest, most effective, and efficient processes to save the lives of people living in the United States with infectious and chronic diseases; and (2) the need to coordinate existing public funding to help small business biotechnology firms whose products may be lost due to domestic economic conditions, and to fund critical paths for small biotechnology drug development and for regulatory review and commercial approval.
Expresses support for: (1) the domestic development and commercialization of biotechnology research by firms meeting small business size standards and collaborations with university-based biotechnology research facilities; and (2) the advancement of U.S.-based commercialization of point of care therapeutics and diagnostics by emerging and small business biotechnology firms for domestic and global use.
Encourages: (1) the development of a national strategic framework to facilitate technological advancements in improving the commercialization processes for small business biotechnology firms; (2) the creation of incentives for small business biotechnology companies that perform basic and applied research through the development and commercialization of biotechnology products and processes and their diffusion into national and local economies; (3) the development of a comprehensive approach to describing disease populations and the production of comprehensive research programs that are current with evolving biotechnology and the unmet needs of diverse patient populations; and (4) the Office of the Secretary of Health and Human Services (HHS) to develop a Federal Biotechnology Coordinating Council representative of small business biotechnology companies, research facilities, and federal agencies with a strategic initiative to facilitate development and preserve these small business biotechnology firms and coordinate resources and funding mechanisms.
Cosponsors 1
Members who signed on, in the order they did. All signed on Jul 29, 2010.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| D-NC | G. K. Butterfield | Jul 29, 2010 |
Actions 2
Everything that happened, newest first.
- Mar 12, 2010Introduced in House
- Mar 12, 2010Referred to the House Committee on Energy and Commerce.
Subjects
Assigned by the Library of Congress. Policy area: Health.
- Advisory bodies
- Department of Health and Human Services
- Drug safety, medical device, and laboratory regulation
- Executive agency funding and structure
- Health
- Health technology, devices, supplies
- Infectious and parasitic diseases
- Medical research
- Public-private cooperation
- Research and development
- Small business
- Technology transfer and commercialization
Text 1
Each version as it was printed, newest first.
- Mar 12, 2010Introduced in House
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this resolution on Congress.gov and govinfo.gov.